Physician profile
Abdullah Sarkar
NPI 1558890335
$21,054.64
in general payments reported to CMS, 2019-2025
22 companies · $2,381 in 2025
The $2,381 reported for 2025 was more than what 86% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $221 · 2020: $139 · 2021: $3,766 · 2022: $7,512 · 2023: $3,501 · 2024: $3,534 · 2025: $2,381.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $5,572 · Food and Beverage: $3,239 · Education: $605.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $5,571.93 |
| Food and Beverage | $3,239.18 |
| Education | $604.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $10,324.30 | 2021-2025 | Acticor 7 Vr-T Dx, Pamira, Amvia Edge |
| Medtronic, INC. | $4,554.38 | 2021-2025 | Micra, Azure Xt Dr Mri Surescan, Selectsecure |
| Abbott Laboratories | $2,100.51 | 2022-2024 | Gallant, Ensite, Ensite Precision |
| Boston Scientific Corporation | $903.68 | 2021-2023 | |
| Medical Device Business Services, INC. | $685.98 | 2024 | Carto 3 |
| Cardiva Medical, INC. | $524.72 | 2022-2023 | Cardiva Vascade Mvp Vvcs 6-12f |
| Amgen INC. | $374.07 | 2021-2022 | |
| Astellas Pharma US INC | $344.48 | 2021-2022 | |
| Kiniksa Pharmaceuticals, LTD. | $247.31 | 2021-2022 | |
| Edwards Lifesciences Corporation | $240.19 | 2019-2021 | |
| Pfizer INC. | $176.08 | 2021-2022 | |
| Biosense Webster, INC. | $145.92 | 2025 | Carto 3 |
| Akcea Therapeutics, INC. | $116.32 | 2020 | |
| Novo Nordisk INC | $54.57 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $54.49 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $43.65 | 2022-2023 | Camzyos |
| Bayer Healthcare Pharmaceuticals INC. | $39.86 | 2022 | |
| Heartflow, INC. | $32.62 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.11 | 2022 | |
| Vital Connect, INC | $25.56 | 2023 | Vitalpatch Rtm |
| Medtronic Vascular, INC. | $22.72 | 2020 | |
| Chiesi USA, INC. | $16.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdullah Sarkar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.